



PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/058,903
		Filing Date	1/28/2002
		First Named Inventor	Timothy Robert Hurley, et al.
		Art Unit	7220
		Examiner Name	Devesh Khare
Sheet 1	of 1	Attorney Docket Number	A0000513-01-AWZ

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
dk	-	Colaco C A L S, et al., "Pharmaceutical Formulation Instability and the Maillard Reaction", Chimica OGGI, Teknoscienze, Milano, IT, Vol. 17, pgs. 32-37 (July 1996)	
dk	-	Field, M.J., et al., "Gabapentin and Pregabalin, But Not Morphine and Amitriptyline, Block Both Static and Dynamic Components of Mechanical Allodynia Induced by Streptozocin in the Rat", Pain, Elsevier Science Publishers, Amsterdam, NL, Vol. 80, pgs 391-398 (1999)	
dk	-	Kumar, V., et al., "Maillard Reaction and Drug Stability", Maillard Reactions in Chemistry, Food and Health, pg. 20-27 (1994)	
dk	-	Lovdahl, Michael J., et al., "Synthesis and characterization of pregabalin lactose conjugate degradation products", J. of Pharma and Biomed Analysis, Vol. 28:5, pg. 917-924 (June 2002)	
dk	-	Maillard, L.C., "Action des acides amines sur les sucres; formation des melanoides par voie methodique", Comptes Rendus Des Seances De L'Academic Des Sciences, Vol. 154, pp. 66-68 (1912)	
dk	-	Taylor, C.P., et al., "Potent and Sterospecific Anticonvulsant Activity of 3-Isobutyl Gaba Relates to In Vitro Bindings at a Novel Site Labeled by Tritiated Gabapentin", Epilepsy Research, Elsevier Science Publishers, Amsterdam, NL, Vol. 14:1, pgs. 11-15 (1993)	
dk	-	Wirth, D.D., et al., "Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine", Journal of Pharmaceutical Sciences, Vol. 87:1, pg. 31-39 (January 1998)	

Examiner Signature	<i>Devesh Khare</i>	Date Considered	5/19/04
--------------------	---------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.